Oxitec Dengue Trials & US Expansion | Break Dengue
Oxitec’s genetically modified mosquitoes are set for field trials in Florida and Texas after receiving an Experimental Use Permit from the EPA, signifying a major step in the fight against dengue and other mosquito-borne diseases. The “Amiable mosquitoes” offer a safe, biodiversity-friendly alternative to customary insecticides, addressing the increasing risk of dengue fever in the U.S. CEO Gray Frandsen highlights the technology’s potential to alleviate strained healthcare systems, exacerbated by COVID-19, and underscores the company’s commitment to building trust through science-based relationships. This innovative approach could redefine vector control, offering a sustainable solution for a healthier future; News Directory 3 has the story. Discover what’s next as oxitec advances its trials.
oxitec Gains EPA Approval for Mosquito Control Field Tests
Oxitec has received an Experimental Use Permit from the Environmental Protection Agency, paving the way for field trials of its genetically modified Aedes aegypti mosquitoes in Florida and Texas. These “Friendly mosquitoes” aim to reduce mosquito populations and combat diseases like dengue and Zika.
Gray Frandsen, CEO of Oxitec, emphasized the importance of this approval. He said the EUP allows them to demonstrate the effectiveness of their technology in the U.S., where the risk of dengue fever and other vector-borne diseases is increasing. Frandsen added that with traditional insecticides losing effectiveness,their Friendly mosquitoes offer a safe,biodiversity-friendly alternative for mosquito control.
The EPA’s stringent review process, along with input from agencies like the Centers for Disease Control, adds credibility to Oxitec’s technology as they seek approvals in other countries, according to Frandsen.
Frandsen acknowledged the challenges of pioneering genetically modified insect technology. He noted that Oxitec’s efforts involve both their specific technology and the broader need for regulatory pathways for new vector control tools.
According to Frandsen, Oxitec prioritizes building trust and maintaining science-based relationships with regulators and stakeholders to navigate the regulatory landscape.
The field trials will generate data to meet EPA requirements for full commercial approval. Oxitec is seeking approval from Florida regulators and local partners before releasing the mosquitoes in a small-scale trial.
Frandsen noted that while COVID-19 has taken center stage in global health, it’s crucial not to ignore the challenges it poses for countries battling dengue. He explained that dengue patients occupy hospital beds and resources needed for COVID-19 patients, and vice versa, straining public health systems.
Frandsen suggested that the pandemic presents an possibility to rethink the approach to fighting dengue and other vector-borne diseases. He advocated for viewing COVID-19, dengue, and malaria as interrelated challenges where progress in one area can benefit others.
Frandsen believes technologies like Oxitec’s can play a significant role in a future where resources and attention are more limited. He also noted that lockdowns could possibly increase dengue rates, especially in dense urban areas, as Aedes aegypti mosquitoes thrive in domestic environments.
What’s next
Oxitec plans to continue working with regulators and local partners to advance its field trials and ultimately deploy its Friendly mosquito technology at scale, contributing to more effective and sustainable mosquito control strategies.